Cancer cases are increasing in adolescents and young adults, while three types of cancers are on the rise for women, per a ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

The CISTO study is the only going prospective study comparing radical cystectomy vs bladder-sparing options for high-grade NMIBC.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

LAS VEGAS -- Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when ...

Further diagnostic tests revealed that Charles has “a form of cancer.” In the months since the announcement, no further ...

Patients with some gastrointestinal tumors were able to be treated with immunotherapy drugs alone and avoid surgery, ...

AUA annual meeting featured the 4 th annual IBCG Bladder Cancer Forum evaluating common problems and controversies in bladder cancer, moderated by Dr. Bernard Bochner, with a debate between Drs. Sia ...

Announcing a new article publication for BIO Integration journal. Bladder cancer (BLCA) is one of the most common malignancies and the second most frequent urogenital tract tumor.

TAR-200 showed high complete response rates in BCG-unresponsive, high-risk non-muscle invasive bladder cancer with CIS in the ...

Cretostimogene grenadenorepvec is an investigational oncolytic immunotherapy that is being studied for the treatment of bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC) that is ...